de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D et al (2012) Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 13(6):607–615. https://doi.org/10.1016/s1470-2045(12)70137-7

Article  PubMed  Google Scholar 

Vorsters A, Bosch FX, Poljak M, Waheed DE, Stanley M, Garland SM (2022) HPV prevention and control - the way forward. Prev Med. 156:106960. https://doi.org/10.1016/j.ypmed.2022.106960

Article  PubMed  PubMed Central  Google Scholar 

de Sanjosé S, Serrano B, Tous S, Alejo M, Lloveras B, Quirós B et al (2018) Burden of human papillomavirus (HPV)-related cancers attributable to HPVs 6/11/16/18/31/33/45/52 and 58. JNCI Cancer Spectr 2(4):pky045. https://doi.org/10.1093/jncics/pky045

Castellsagué X, Ault KA, Bosch FX, Brown D, Cuzick J, Ferris DG et al (2016) Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region. Papillomavirus Res. 2:61–69. https://doi.org/10.1016/j.pvr.2016.03.002

Article  PubMed  PubMed Central  Google Scholar 

Lei J, Ploner A, Elfström KM, Wang J, Roth A, Fang F et al (2020) HPV Vaccination and the risk of invasive cervical cancer. N Engl J Med. 383(14):1340–1348. https://doi.org/10.1056/NEJMoa1917338

Article  CAS  PubMed  Google Scholar 

Huh WK, Joura EA, Giuliano AR, Iversen OE, de Andrade RP, Ault KA et al (2017) Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial. Lancet. 390(10108):2143–2159. https://doi.org/10.1016/s0140-6736(17)31821-4

Article  CAS  PubMed  Google Scholar 

Chaturvedi AK, Graubard BI, Broutian T, Pickard RKL, Tong ZY, Xiao W et al (2018) Effect of prophylactic human papillomavirus (HPV) vaccination on oral HPV infections among young adults in the United States. J Clin Oncol. 36(3):262–267. https://doi.org/10.1200/jco.2017.75.0141

Article  CAS  PubMed  Google Scholar 

Athanasiou A, Bowden S, Paraskevaidi M, Fotopoulou C, Martin-Hirsch P, Paraskevaidis E et al (2020) HPV vaccination and cancer prevention. Best Pract Res Clin Obstet Gynaecol. 65:109–124. https://doi.org/10.1016/j.bpobgyn.2020.02.009

Article  CAS  PubMed  Google Scholar 

Rafael TS, Rotman J, Brouwer OR, van der Poel HG, Mom CH, Kenter GG et al (2022) Immunotherapeutic approaches for the treatment of HPV-associated (pre-)cancer of the cervix, vulva and penis. Journal of Clinical Medicine. 11(4):1101

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim TJ, Jin HT, Hur SY, Yang HG, Seo YB, Hong SR et al (2014) Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients. Nat Commun 5:5317. https://doi.org/10.1038/NCOMMS6317

Bagarazzi ML, Yan J, Morrow MP, Shen X, Parker RL, Lee JC et al (2012) Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med 4(155):155ra138. https://doi.org/10.1126/scitranslmed.3004414

Trimble CL, Morrow MP, Kraynyak KA, Shen X, Dallas M, Yan J et al (2015) Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet (London, England). 386(10008):2078–2088. https://doi.org/10.1016/S0140-6736(15)00239-1

Article  CAS  PubMed  PubMed Central  Google Scholar 

van Seters M, van Beurden M, de Craen AJM (2005) Is the assumed natural history of vulvar intraepithelial neoplasia III based on enough evidence? A systematic review of 3322 published patients. Gynecologic Oncology. 97(2):645–651. https://doi.org/10.1016/j.ygyno.2005.02.012

Article  PubMed  Google Scholar 

Kenter GG, Welters MJP, Valentijn ARPM, Lowik MJG, Berends-van der Meer DMA, Vloon APG et al (2009) Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. The New England journal of medicine. 361(19):1838–1847. https://doi.org/10.1056/NEJMOA0810097

Article  CAS  PubMed  Google Scholar 

Van Poelgeest M, Welters MJP, Vermeij R, Stynenbosch LFM, Loof NM, Berends-van der Meer DMA et al (2016) Vaccination against oncoproteins of HPV16 for noninvasive vulvar/vaginal lesions: lesion clearance is related to the strength of the T-cell response. Clinical Cancer Research. 22(10):2342–2350. https://doi.org/10.1158/1078-0432.CCR-15-2594

Article  CAS  PubMed  Google Scholar 

Kenter GG, Welters MJP, Valentijn ARPM, Löwik MJG, Berends-van Der Meer DMA, Vloon APG et al (2008) Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clinical Cancer Research. 14(1):169–177. https://doi.org/10.1158/1078-0432.CCR-07-1881

Article  CAS  PubMed  Google Scholar 

van Poelgeest MIE, Welters MJP, van Esch EMG, Stynenbosch LFM, Kerpershoek G, El VPVM et al (2013) HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial. Journal of Translational Medicine. 11(1):88. https://doi.org/10.1186/1479-5876-11-88

Article  CAS  PubMed  PubMed Central  Google Scholar 

Van Der Sluis TC, Van Duikeren S, Huppelschoten S, Jordanova ES, Nejad EB, Sloots A et al (2015) Vaccine-induced tumor necrosis factor- producing T cells synergize with cisplatin to promote tumor cell death. Clinical Cancer Research. 21(4):781–794. https://doi.org/10.1158/1078-0432.CCR-14-2142

Article  CAS  PubMed  Google Scholar 

Beyranvand Nejad E, van der Sluis TC, van Duikeren S, Yagita H, Janssen GM, van Veelen PA et al (2016) Tumor eradication by cisplatin is sustained by CD80/86-mediated costimulation of CD8+ T cells. Cancer Research. 76(20):6017–6029. https://doi.org/10.1158/0008-5472.Can-16-0881

Article  CAS  PubMed  Google Scholar 

Welters MJ, Van Der Sluis TC, Van Meir H, Loof NM, Van Ham VJ, Van Duikeren S et al (2016) Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses. Sci Transl Med 8(334):334ra52. https://doi.org/10.1126/SCITRANSLMED.AAD8307

Melief CJM, Welters MJP, Vergote I, Kroep JR, Kenter GG, Ottevanger PB et al (2020) Strong vaccine responses during chemotherapy are associated with prolonged cancer survival. Sci Transl Med 12(535):eaaz8235. https://doi.org/10.1126/SCITRANSLMED.AAZ8235

Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. The New England journal of medicine. 375(19):1856–1867. https://doi.org/10.1056/NEJMOA1602252

Article  PubMed  PubMed Central  Google Scholar 

Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, De Castro G Jr et al (2019) Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 394(10212):1915–1928. https://doi.org/10.1016/s0140-6736(19)32591-7

Article  CAS  PubMed  Google Scholar 

Massarelli E, William W, Johnson F, Kies M, Ferrarotto R, Guo M et al (2019) Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable human papillomavirus 16-related cancer: a phase 2 clinical trial. JAMA oncology. 5(1):67–73. https://doi.org/10.1001/JAMAONCOL.2018.4051

Article  PubMed  Google Scholar 

Sousa LG, Rajapakshe K, Rodriguez Canales J, Chin RL, Feng L, Wang Q et al (2022) ISA101 and nivolumab for HPV-16(+) cancer: updated clinical efficacy and immune correlates of response. J Immunother Cancer. 10(2):e004232. https://doi.org/10.1136/jitc-2021-004232

Article  PubMed  PubMed Central  Google Scholar 

Saxena M, van der Burg SH, Melief CJM, Bhardwaj N (2021) Therapeutic cancer vaccines. Nat Rev Cancer. 21(6):360–378. https://doi.org/10.1038/s41568-021-00346-0

Article  CAS  PubMed  Google Scholar 

Melssen MM, Fisher CT, Slingluff CL, Melief CJM (2022) Peptide emulsions in incomplete Freund’s adjuvant create effective nurseries promoting egress of systemic CD4+ and CD8+ T cells for immunotherapy of cancer. Journal for ImmunoTherapy of Cancer. 10(9):e004709. https://doi.org/10.1136/jitc-2022-004709

Article  PubMed Central  Google Scholar 

Borst J, Ahrends T, Bąbała N, Melief CJM, Kastenmüller W (2018) CD4 + T cell help in cancer immunology and immunotherapy. Nature reviews Immunology. 18(10):635–647. https://doi.org/10.1038/S41577-018-0044-0

Article  CAS  PubMed  Google Scholar 

Stevanović S, Draper LM, Langhan MM, Campbell TE, Kwong ML, Wunderlich JR et al (2015) Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol. 33(14):1543–1550. https://doi.org/10.1200/jco.2014.58.9093

Article  PubMed  PubMed Central  Google Scholar 

Nagarsheth NB, Norberg SM, Sinkoe AL, Adhikary S, Meyer TJ, Lack JB et al (2021) TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers. Nat Med. 27(3):419–425. https://doi.org/10.1038/s41591-020-01225-1

Article  CAS  PubMed  PubMed Central  Google Scholar